June 11, 2026

PeptiDream Inc.
https://www.peptidream.com/en/
(TSE Prime Market: 4587)
PDRadiopharma Inc.
https://www.pdradiopharma.com/en/

PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of ^{64}Cu-PSMA-I&T for Prostate Cancer in Japan

- Completion of patient dosing in the registrational Phase 2 clinical trial of **^{64}Cu-PSMA-I&T** —a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells
- Data analysis is now underway to support future regulatory submission in Japan

KANAGAWA, JAPAN – June 11, 2026 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo Stock Exchange: 4587), PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan, “PDRadiopharma”), a wholly owned subsidiary of PeptiDream, and Curium Group, a world leader in nuclear medicine (CEO: Renaud Dehareng, Headquarters: Boston, Massachusetts, the United States), today announced that patient dosing has been completed in the registrational Phase 2 clinical trial (jRCT: 2031250225) of ^{64}Cu-PSMA-I&T in Japan.

^{64}Cu-PSMA-I&T is a positron emission tomography (PET) radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), a cell-surface protein commonly highly expressed in prostate cancer cells. ^{64}Cu-PSMA-I&T is being assessed as a diagnostic PET imaging agent labeled with the radioisotope Copper-64.

The trial is being conducted under the strategic collaboration between Curium and PDRadiopharma, a wholly owned subsidiary of PeptiDream. The open-label, single-arm Phase 2 study is designed to evaluate the sensitivity, specificity and safety of ^{64}Cu-PSMA-I&T in Japanese patients newly diagnosed with unfavorable intermediate, high or very high-risk prostate cancer and scheduled for prostatectomy with pelvic lymph node dissection.

The results from this study, together with data from Curium’s ongoing global clinical trials, are expected to support future regulatory submission in Japan.

In parallel, as announced in February 2026, a registrational clinical trial of the therapeutic counterpart, ^{177}Lu-PSMA-I&T, is being advanced to evaluate its efficacy and safety in patients

with metastatic castration-resistant prostate cancer (mCRPC), as part of a theranostic approach.

Patrick C. Reid, President & CEO of PeptiDream commented: *"The completion of patient dosing marks an important milestone in the development of ^{64}Cu-PSMA-I&T in Japan. This program represents a key component of our growing radiopharmaceutical pipeline and our broader theranostics strategy. We would like to thank the patients, investigators and clinical sites for their participation and support."*

Masato Murakami, President of PDRadiopharma & Executive Vice President of PeptiDream commented: ''*We are pleased to have completed patient dosing in this clinical trial for ^{64}Cu-PSMA-I&T in Japan. This milestone reflects the strong collaboration between PDRadiopharma, PeptiDream and Curium, and represents an important step in the development of PSMA-targeted theranostics for patients with prostate cancer in Japan. We would like to express our sincere appreciation to the patients, investigators and clinical staff who have supported this study, and we will continue to work closely with our partners toward the next stages of development in Japan."*

Renaud Dehareng, CEO of Curium Group commented: *"Conducting these trials, in partnership with PeptiDream and PDRadiopharma, marks a significant milestone in our mission to expand access to cutting-edge radiopharmaceuticals to patients with prostate cancer across Asia. By combining Curium's global development expertise with PDRadiopharma's deep local knowledge and infrastructure, we are well-positioned to deliver transformative solutions to patients with prostate cancer in Japan."*

About Prostate Cancer

Prostate cancer continues to be widely prevalent in Japan. Annually, there are approximately 90,000 – 100,000 new cases (*1).

*1: National Cancer Center Japan

Global Clinical Trial Progress

Phase 3 ECLIPSE trial: ^{177}Lu-PSMA-I&T, a PSMA-targeting ligand conjugated with the radioisotope Lutetium-177, has been tested by Curium in a global pivotal Phase 3 ECLIPSE trial (ClinicalTrials.gov identifier; NCT05204927). It reported that the primary endpoint was met, demonstrating a statistically significant and clinically meaningful benefit for patients with mCRPC.

Phase 3 SOLAR RECUR and SOLAR STAGE trial: ^{64}Cu-PSMA-I&T trials are being conducted to diagnose biochemical recurrence of prostate cancer (SOLAR RECUR trial, ClinicalTrials.gov identifier NCT06235099) and for men newly diagnosed with unfavorable intermediate to very high-risk prostate cancer, electing to undergo surgery (SOLAR STAGE trial, ClinicalTrials.gov identifier NCT06235151). The first in human Phase 1/2 SOLAR trial met the co-primary endpoints of region-level correct localization rate and patient-level correct detection rate in patients with histologically-proven metastatic prostate cancer.

Partnership Details

Under the terms of the partnership, PDRadiopharma and Curium will jointly collaborate on clinical development activities of ^{177}Lu-PSMA-I&T and ^{64}Cu-PSMA-I&T in Japan, with PDRadiopharma leading regulatory filing, manufacturing, commercialization, and distribution activities in Japan. Curium will continue to lead global development of the two agents and support PDRadiopharma through technology transfer to support the set-up of manufacturing

lines in Japan – including a high throughput copper-64 manufacturing line based on Curium's proprietary technology.

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field in radiopharmaceuticals, since it started its business in 1968. PDRadiopharma currently markets 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit http://www.pdradiopharma.com/en/

About Curium

Curium Pharma is a leading global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that transform the way cancer is diagnosed and treated. Headquartered in Boston with offices around the world, Curium's mission is to find new and better ways to diagnose and treat cancer.

With a global footprint that extends to more than 70 countries, a skilled and dedicated team of over 5,000 employees, and four manufacturing sites, Curium is uniquely qualified to meet the significant supply and distribution of established products that underlie success in the radiopharmaceuticals market. Curium's global leadership is embodied in a diverse and extensive portfolio of over 45 products, that advance patient care for a wide range of cancers.

Curium's pioneering legacy in nuclear medicine is the foundation of the company's dedication to innovation and portfolio expansion to cancer therapeutics, particularly in neuroendocrine tumors and with a late-stage pipeline exploring opportunities in prostate cancer.

To learn more, visit www.curiumpharma.com.

Inquiries:

PeptiDream Inc.
Contact: Yuko Okimoto, IR & Corporate Communications
Email: info@peptidream.com
Website: https://www.peptidream.com/en/

X: https://x.com/PeptidreamInc
LinkedIn: https://www.linkedin.com/company/peptidream

PDRadiopharma Inc.
Contact: Noriko Tanaka, General Affairs
Email: s-info-hq@pdradiopharma.com

Curium
Camilla Campbell
VP, Head of Global Communications
communications@curiumpharma.com
Website: www.curiumpharma.com